Xspray Pharma: Tasigna approved for pediatric patients
Research Note
2018-03-23
07:36
The FDA has approved Novartis’ Tasigna for pediatric Ph+CML patients, resulting in a six month pediatric exclusivity period after primary patent expiry. This narrows the HyNap-Nilo patent window, but as income is far into the future and the increased patient population makes up for lost value, the net effect is zero.
MS
Mathias Spinnars
Disclosures and disclaimers